Novel thrombotic function of a human SNP in STXBP5 revealed by CRISPR/Cas9 gene editing in mice

Qiuyu Martin Zhu, Kyung Ae Ko, Sara Ture, Michael A. Mastrangelo, Ming Huei Chen, Andrew D. Johnson, Christopher J. O'Donnell, Craig N. Morrell, Joseph M. Miano, Charles J. Lowenstein

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Objective - To identify and characterize the effect of a SNP (single-nucleotide polymorphism) in the STXBP5 locus that is associated with altered thrombosis in humans. GWAS (genome-wide association studies) have identified numerous SNPs associated with human thrombotic phenotypes, but determining the functional significance of an individual candidate SNP can be challenging, particularly when in vivo modeling is required. Recent GWAS led to the discovery of STXBP5 as a regulator of platelet secretion in humans. Further clinical studies have identified genetic variants of STXBP5 that are linked to altered plasma von Willebrand factor levels and thrombosis in humans, but the functional significance of these variants in STXBP5 is not understood. Approach and Results - We used CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated 9) techniques to produce a precise mouse model carrying a human coding SNP rs1039084 (encoding human p. N436S) in the STXBP5 locus associated with decreased thrombosis. Mice carrying the orthologous human mutation (encoding p. N437S in mouse STXBP5) have lower plasma von Willebrand factor levels, decreased thrombosis, and decreased platelet secretion compared with wild-type mice. This thrombosis phenotype recapitulates the phenotype of humans carrying the minor allele of rs1039084. Decreased plasma von Willebrand factor and platelet activation may partially explain the decreased thrombotic phenotype in mutant mice. Conclusions - Using precise mammalian genome editing, we have identified a human nonsynonymous SNP rs1039084 in the STXBP5 locus as a causal variant for a decreased thrombotic phenotype. CRISPR/Cas9 genetic editing facilitates the rapid and efficient generation of animals to study the function of human genetic variation in vascular diseases.

Original languageEnglish (US)
Pages (from-to)264-270
Number of pages7
JournalArteriosclerosis, thrombosis, and vascular biology
Volume37
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

    Fingerprint

Keywords

  • gene editing
  • genome-wide association study
  • phenotype
  • thrombosis
  • von Willebrand factor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Zhu, Q. M., Ko, K. A., Ture, S., Mastrangelo, M. A., Chen, M. H., Johnson, A. D., O'Donnell, C. J., Morrell, C. N., Miano, J. M., & Lowenstein, C. J. (2017). Novel thrombotic function of a human SNP in STXBP5 revealed by CRISPR/Cas9 gene editing in mice. Arteriosclerosis, thrombosis, and vascular biology, 37(2), 264-270. https://doi.org/10.1161/ATVBAHA.116.308614